Redmile Group, LLC's Form 4 filing
ADC Therapeutics SA (ADCT) · filed Dec 13, 2024
- Accession no.
- 0001104659-24-128575
- Filed
- Dec 13, 2024, 9:00 PM ET
- Trade date
- Dec 11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $609.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Redmile Group, LLCCIK 0001425738 | 10% Owner |
| Green JeremyCIK 0001650527 | 10% Owner |
| RedCo II Master Fund, L.P.CIK 0001921783 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 11, 2024 | Common Shares, par value CHF 0.08 per share | PPurchaseAcquired | +50,000 | $2.28F1 | +$114,000 | 15,616,731 | Indirect | |
| Dec 11, 2024 | Common Shares, par value CHF 0.08 per share | PPurchaseAcquired | +50,000 | $3.81F2 | +$190,500 | 15,666,731 | Indirect | |
| Dec 11, 2024 | Common Shares, par value CHF 0.08 per share | PPurchaseAcquired | +50,000 | $2.28F1 | +$114,000 | 13,095,712 | Direct | |
| Dec 11, 2024 | Common Shares, par value CHF 0.08 per share | PPurchaseAcquired | +50,000 | $3.81F2 | +$190,500 | 13,145,712 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.165 to $2.4, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.64 to $3.9, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.
Remarks
The purchases reported herein were effected within a period of less than six months from deemed sales reported in the Form 4 filed by the Reporting Persons on December 6, 2024. However, the purchases reported herein were effected at a price higher than the previous deemed sales that were also reported in the Form 4 filed December 6, 2024, such that no profits have been earned by the Reporting Persons, and so the Reporting Persons have no additional liability under Section 16(b).